|
U.S. FDA approves ABRYSVO™, Pfizer's vaccine for the prevention of respiratory syncytial virus (RSV) in older adults
|
01 June 2023 |
|
Pfizer's PAXLOVID™ receives FDA approval for adult patients at high risk of progression to severe COVID-19
|
25 May 2023 |
|
FDA Advisory Committee votes in support of approval for Pfizer's vaccine candidate to help prevent RSV in infants through maternal immunization
|
19 May 2023 |
|
Thermo Fisher Scientific & Pfizer partner to expand localized access to next generation sequencing-based testing for cancer patients in international markets
|
18 May 2023 |
|
U.S. FDA approves PREVNAR 20®, Pfizer's 20-valent pneumococcal conjugate vaccine for infants and children
|
27 April 2023 |
|
FDA accepts Pfizer's Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
|
05 April 2023 |
|
Pfizer invests $43 billion to battle cancer
|
13 March 2023 |
|
Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spray receives FDA approval
|
10 March 2023 |
|
Pfizer receives positive FDA Advisory Committee votes supporting potential approval for vaccine candidate to help combat RSV in older adults
|
01 March 2023 |
|
Pfizer's elranatamab receives FDA and EMA filing acceptance
|
22 February 2023 |
|
Pfizer announces The Lancet Neurology has published Phase 3 data for zavegepant for the acute treatment of migraine in adults
|
17 February 2023 |
|
Pfizer reports record full-year 2022 results
|
02 February 2023 |
|
Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
|
18 January 2023 |
|
Pfizer announces positive top-line results from Phase 3 study of hemophilia B gene therapy candidate
|
29 December 2022 |
|
Pfizer announces FDA and EMA acceptance of etrasimod regulatory submissions for ulcerative colitis
|
26 December 2022 |
|
Pfizer and Clear Creek Bio to collaborate on a research program targeting SARS-CoV-2 papain-like protease
|
06 December 2022 |
|
Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster
|
24 November 2022 |
|
Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster for children 5 through 11 years of age in European Union
|
11 November 2022 |
|
Pfizer's elranatamab granted FDA Breakthrough Therapy Designation for relapsed or refractory multiple myeloma
|
04 November 2022 |
|
Pfizer and BioNTech announce positive early data from clinical trial of Omicron BA.4/BA.5-adapted bivalent booster in individuals 18 years and older
|
25 October 2022 |